232 related articles for article (PubMed ID: 26324949)
1. Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up.
Chen DY; Chen YM; Hsieh TY; Hung WT; Hsieh CW; Chen HH; Tang KT; Lan JL
Rheumatology (Oxford); 2016 Jan; 55(1):143-8. PubMed ID: 26324949
[TBL] [Abstract][Full Text] [Related]
2. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis.
Chen DY; Chen YM; Tsai WC; Tseng JC; Chen YH; Hsieh CW; Hung WT; Lan JL
Ann Rheum Dis; 2015 Mar; 74(3):e16. PubMed ID: 24442879
[TBL] [Abstract][Full Text] [Related]
3. Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement.
Bouman C; van Herwaarden N; van den Hoogen F; van der Maas A; van den Bemt B; den Broeder AA
Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):597-604. PubMed ID: 28425772
[TBL] [Abstract][Full Text] [Related]
4. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
[TBL] [Abstract][Full Text] [Related]
5. Key findings towards optimising adalimumab treatment: the concentration-effect curve.
Pouw MF; Krieckaert CL; Nurmohamed MT; van der Kleij D; Aarden L; Rispens T; Wolbink G
Ann Rheum Dis; 2015 Mar; 74(3):513-8. PubMed ID: 24326008
[TBL] [Abstract][Full Text] [Related]
6. Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study.
Tanaka Y; Yamanaka H; Ishiguro N; Miyasaka N; Kawana K; Kimura J; Agata N; Takeuchi T
Arthritis Res Ther; 2017 Mar; 19(1):56. PubMed ID: 28288682
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab drug and antidrug antibody levels do not predict flare risk after stopping adalimumab in RA patients with low disease activity.
Lamers-Karnebeek FBG; Jacobs JWG; Radstake TRDJ; van Riel PLCM; Jansen TL
Rheumatology (Oxford); 2019 Mar; 58(3):427-431. PubMed ID: 30383251
[TBL] [Abstract][Full Text] [Related]
8. Association of female sex and positive rheumatoid factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid arthritis: results from the SWEFOT trial population.
Hambardzumyan K; Hermanrud C; Marits P; Vivar N; Ernestam S; Wallman JK; van Vollenhoven RF; Fogdell-Hahn A; Saevarsdottir S;
Scand J Rheumatol; 2019 Sep; 48(5):362-366. PubMed ID: 31244356
[No Abstract] [Full Text] [Related]
9. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity.
Harigai M; Takeuchi T; Tanaka Y; Matsubara T; Yamanaka H; Miyasaka N
Mod Rheumatol; 2012 Nov; 22(6):814-22. PubMed ID: 22270346
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study.
Emery P; Burmester GR; Naredo E; Sinigaglia L; Lagunes I; Koenigsbauer F; Conaghan PG
Ann Rheum Dis; 2020 Aug; 79(8):1023-1030. PubMed ID: 32404343
[TBL] [Abstract][Full Text] [Related]
11. Improved adalimumab dose decision with comprehensive diagnostics data.
Zänker M; Becher G; Arbach O; Maurer M; Stuhlmüller B; Schäfer A; Strohner P; Brand J
Clin Exp Rheumatol; 2018; 36(1):136-139. PubMed ID: 28850025
[TBL] [Abstract][Full Text] [Related]
12. High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab.
Hattori Y; Kojima T; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Oguchi T; Kanayama Y; Miyake H; Kato T; Takagi H; Hayashi M; Ito T; Shioura T; Takahashi N; Ishikawa H; Funahashi K; Ishiguro N
Mod Rheumatol; 2018 Jan; 28(1):119-125. PubMed ID: 28463029
[TBL] [Abstract][Full Text] [Related]
13. Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Im
Emery P; Burmester GR; Naredo E; Zhou Y; Hojnik M; Conaghan PG
BMJ Open; 2018 Feb; 8(2):e019007. PubMed ID: 29490959
[TBL] [Abstract][Full Text] [Related]
14. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562
[TBL] [Abstract][Full Text] [Related]
15. Low Percentage of Signal Regulatory Protein α/β
Magill L; Adriani M; Berthou V; Chen K; Gleizes A; Hacein-Bey-Abina S; Hincelin-Mery A; Mariette X; Pallardy M; Spindeldreher S; Szely N; Isenberg DA; Manson JJ; Jury EC; Mauri C
Front Immunol; 2018; 9():2865. PubMed ID: 30568660
[TBL] [Abstract][Full Text] [Related]
16. Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations.
Van den Bosch F; Kavanaugh A; Kron M; Kupper H; Mease PJ
J Rheumatol; 2015 Jun; 42(6):952-9. PubMed ID: 25834212
[TBL] [Abstract][Full Text] [Related]
17. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy.
Furst DE; Kavanaugh A; Florentinus S; Kupper H; Karunaratne M; Birbara CA
Rheumatology (Oxford); 2015 Dec; 54(12):2188-97. PubMed ID: 26199453
[TBL] [Abstract][Full Text] [Related]
18. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
Detert J; Bastian H; Listing J; Weiß A; Wassenberg S; Liebhaber A; Rockwitz K; Alten R; Krüger K; Rau R; Simon C; Gremmelsbacher E; Braun T; Marsmann B; Höhne-Zimmer V; Egerer K; Buttgereit F; Burmester GR
Ann Rheum Dis; 2013 Jun; 72(6):844-50. PubMed ID: 22739990
[TBL] [Abstract][Full Text] [Related]
19. 5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study.
Yamaguchi A; Hirata S; Kubo S; Fukuyo S; Hanami K; Nakano K; Nakayamada S; Saito K; Tanaka Y
Mod Rheumatol; 2020 Sep; 30(5):799-806. PubMed ID: 31814496
[No Abstract] [Full Text] [Related]
20. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.
Tanaka Y; Hirata S; Kubo S; Fukuyo S; Hanami K; Sawamukai N; Nakano K; Nakayamada S; Yamaoka K; Sawamura F; Saito K
Ann Rheum Dis; 2015 Feb; 74(2):389-95. PubMed ID: 24288014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
